Minakem Minakem

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"CellResearch Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cell Research Corporation (CRC) Announces Positive Results of Phase I Study for CorLiCyte\u00ae","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase I","country":"SINGAPORE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"CellResearch Corporation"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Product Type
            filter News Type

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Product Type

              Companies

              CellResearch Corporation

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Singapore
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cell Research Corporation (CRC) Announces Positive Results of Phase I Study for CorLiCyte®

              Details:

              CorLiCyte® is a live mesenchymal stem cell therapy derived from human umbilical cord lining stem cells, with a proprietary optimised expression of cytokines, growth and cellular factors for the treatment of a number of serious health conditions.

              Lead Product(s): Human Umbilical Cord Derived Mesenchymal Stem Cells

              Therapeutic Area: Podiatry Product Name: CorLiCyte

              Highest Development Status: Phase I Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 16, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Skyepharma, an Expert and Agile CDMO Partner for tailor-made solutions in complex oral solids and bioproduction.
              SuanFarma is present in all origins: Natural, Chemical & Biotechnological.
              Post Enquiry
              POST ENQUIRY